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Abstract
Background: The mechanisms by which tumor-specific T cells induce regression of established
metastases are not fully characterized. In using the poorly immunogenic B16BL6-D5 (D5)
melanoma model we reported that T cell-mediated tumor regression can occur independently of
perforin, IFN-γ or the combination of both. Characterization of regressing pulmonary metastases
identified macrophages as a major component of the cells infiltrating the tumor after adoptive
transfer of effector T cells. This led us to hypothesize that macrophages played a central role in
tumor regression following T-cell transfer. Here, we sought to determine the factors responsible
for the infiltration of macrophages at the tumor site.
Methods: These studies used the poorly immunogenic D5 melanoma model. Tumor-specific
effector T cells, generated from tumor vaccine-draining lymph nodes (TVDLN), were used for
adoptive immunotherapy and in vitro analysis of chemokine expression. Cellular infiltrates into
pulmonary metastases were determined by immunohistochemistry. Chemokine expression by the
D5 melanoma following co-culture with T cells, IFN-γ or TNF-α was determined by RT-PCR and
ELISA. Functional activity of chemokines was confirmed using a macrophage migration assay. T cell
activation of macrophages to release nitric oxide (NO) was determined using GRIES reagent.
Results: We observed that tumor-specific T cells with a type 1 cytokine profile also expressed
message for and secreted RANTES, MIP-1α and MIP-1β following stimulation with specific tumor.
Unexpectedly, D5 melanoma cells cultured with IFN-γ or TNF-α, two type 1 cytokines expressed
by therapeutic T cells, secreted Keratinocyte Chemoattractant (KC), MCP-1, IP-10 and RANTES
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and expressed mRNA for MIG. The chemokines released by T cells and cytokine-stimulated tumor
cells were functional and induced migration of the DJ2PM macrophage cell line. Additionally,
tumor-specific stimulation of wt or perforin-deficient (PKO) effector T cells induced macrophages
to secrete nitric oxide (NO), providing an additional effector mechanism for T cell-mediated tumor
regression.
Conclusion: These data suggest two possible sources for chemokine secretion that stimulates
macrophage recruitment to the site of tumor metastases. Both appear to be initiated by T cell
recognition of specific antigen, but one is dependent on the tumor cells to produce the chemokines
that recruit macrophages.
Background
The adoptive transfer of tumor-specific T cells can mediate
tumor regression and long-lasting anti-tumor immunity
in the B16BL6-D5 (D5) murine melanoma model [1-3].
Examination of the effector mechanisms responsible for
tumor regression showed that effector T cells deficient in
perforin, IFN-γ or both perforin and IFN-γ were still able
to cause tumor regression [2-4]. However, if TNF was neu-
tralized in T cells deficient in perforin and IFN-γ signifi-
cant tumor regression was no longer observed [4]. These
results suggest a triad of molecules that can "compensate"
for one another and define a minimal functional require-
ment for T cells to mediate tumor regression in this
model. Further, these findings led us to question how cells
deficient in perforin, a molecule essential for direct cyto-
toxicity, induced tumor regression.
Immunohistochemical analyses of pulmonary metastases
identified macrophages to be a dominant component of
the cellular infiltrate following adoptive transfer of thera-
peutic T cells and IL-2. These same infiltrates were not
seen in progressively growing tumors or animals treated
with IL-2 alone [2]. Since this occurred within 24 hours of
adoptive T cell transfer we considered that these infiltrat-
ing cells might play a role in tumor regression. But what
triggered the influx of monocytes? Numerous reports have
identified a correlation between a tumor-specific type 1
cytokine profile and therapeutic T cells [1,5-8]. Since the
CC-chemokines MCP-1 (CCL2), MIP-1α, (CCL3), MIP-1β
(CCL4), and RANTES (CCL5), as well as the CXC chemok-
ine IP-10 (CXCL10), and MIG (CXCL9) were found to be
associated with a type-1 T cell response [9-11], we posited
that there may be a link between expression of these
chemokines, macrophage infiltration of tumor metastases
and therapeutic efficacy.
Chemokines are small polypeptide signaling molecules
that bind to and activate a family of seven transmembrane
G protein-coupled chemokine receptors. Chemokines are
responsible for the selective recruitment and activation of
mononuclear cells [12,13], and they induce the directed
migration of leukocytes, stimulate their adhesion and
trans-endothelial migration [14,15]. Thus, we considered
chemokines might be responsible for the infiltration of
monocytes into pulmonary metastases. Here we investi-
gated chemokine release following the encounter of ther-
apeutic T cells with the specific tumor cells they
recognized and how these interactions might promote
tumor destruction.
Methods
Mice
Female C57BL/6J (wt), C57BL/6 -PFPtm1Sdz (PKO) mice
were purchased from the Jackson Laboratory (Bar Harbor,
ME) and maintained in a specific pathogen-free environ-
ment. Mice were generally 8 to 12 weeks old at the time of
experimentation. Recognized principles of laboratory ani-
mal care were followed (Guide for the Care and Use of
Laboratory Animals, National Research Council, 1996).
All animal protocols were approved by the Earle A. Chiles
Research Institute Animal Care and Use Committee.
Cell lines
D5 is a poorly immunogenic subclone of the spontane-
ously arising B16BL6 melanoma. An early passage of the
original tumor was subcloned by limiting dilution. D5-G6
is a stable clone originally transduced with a murine GM-
CSF retroviral MFG vector [16]. D5-G6 cells secrete
approximately 200 ng/ml/106 cells/24 h GM-CSF. MPR-4
is a transformed prostate tumor cell line generated from a
C57BL/6 mouse [17]. MCA-310 (H-2b) is a methylcholan-
threne-induced sarcoma and DJ2PM is a transformed
macrophage cell line (generously provided by A.V. Pal-
leroni, Hoffmann-La Roche Inc., Nutley, NJ, USA), both
were generated in C57BL/6 mice [18].
Reagents
The 145-2c11 hybridoma (anti-CD3) was a gift from J. A.
Bluestone (University of Chicago, Chicago, IL). Recom-
binant murine IFN-γ was purchased from Pepro-Tech
(London, UK) and recombinant human TNFα was pro-
vided by Cetus (Emeryville, CA). Recombinant human IL-
2 was provided by Chiron Inc. (Emeryville, CA). The anti-
CD4 (GK1.5, TIB-207), anti-CD8 (2.43, TIB-210), anti-
NK1.1 (PK136, HB-191), anti-Mac-1 (M1/70, TIB-128),
and rat anti-mouse IFN-γ (IgG1, R4-6A2) hybridomasJournal of Translational Medicine 2007, 5:56 http://www.translational-medicine.com/content/5/1/56
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were obtained from American Type Culture Collection
(Manassas, VA). Ascites were prepared in DBA/2 mice
primed with pristane and immuno-suppressed by injec-
tion with 200 mg/kg cyclophosphamide. Purified anti-
granulocyte Ab, GR-1, FITC- and PE-labeled isotype con-
trol rat IgG, hamster IgG, and mAb against CD3, CD4, and
CD8 were purchased from PharMingen (San Diego, CA).
Culture conditions
Lymphocytes and tumor cells were cultured in complete
medium (CM), which consisted of RPMI 1640 containing
0.1 mM non-essential amino acids, 1 mM sodium pyru-
vate, 2 mM L-glutamine, and 50 mg/ml of gentamicin sul-
fate (Bio Whittaker, Walkersville, MD.). This was further
supplemented with 50 mM 2-mercaptoethanol (Aldrich,
Milwaukee, WI), and 10% fetal bovine serum (GIBCO
BRL, Grand Island, NY). Tumor cells were harvested 2-to
3 times per week by brief trypsinization (Trypsin, Bio
Whittaker, Walkersville, MD) and maintained in T-75 or
T-150 culture flasks.
Generation of effector T cells from tumor vaccine-draining 
lymph nodes (TVDLN)
D5-G6 tumor cells were harvested by trypsinization,
washed twice with HBSS and resuspended at 2 × 107 cells
per ml. One million D5-G6 tumor cells were injected s.c.
into both hind and fore flanks of wt and PKO mice. Eight
days following vaccination the draining superficial
inguinal and axillary lymph nodes were harvested and
TVDLN isolated. Effector T cells were generated by cultur-
ing TVDLN at 2 × 106 cells per ml in CM with 50 ul of a
1:40 dilution of 2C11 ascites (anti-CD3) as described pre-
viously [1]. After 2 days of activation, T cells were har-
vested and expanded in CM containing 60 IU rhIL-2/ml
for 3 additional days. Effector T cells were then harvested,
washed twice in HBSS, counted and used for adoptive
transfer and in vitro assays.
Adoptive Immunotherapy and Immunohistochemical 
analysis of tumor-bearing lungs
Experimental pulmonary metastases were established by
i.v. inoculation of 2 × 105 D5 tumor cells. Mice with 3-day
established pulmonary metastases received 90,000 IU IL-
2 alone or together with the adoptive transfer of wt or
PKO effector T cells (35 × 106). Twenty-four hours later
mice were killed, and frozen sections of the lungs were
prepared. Tissue sections were blocked with avidin and
biotin and then stained with a control rat IgG, anti-CD4,
anti-CD8, anti-NK1.1, anti-Mac-1, or anti-Gr-1 Abs (spec-
ified above). Sections were washed and incubated with
biotin-labeled goat anti-rat IgG, washed, and incubated
with the Vectastain ABC reagent (Vector Laboratories, Bur-
lingame, CA). Slides were developed using diaminobenzi-
dine solution (Vector) and counterstained with
hematoxylin. Images were acquired using a micropub-
lisher CCD camera and Q capture 2.18.0 software (Q
imaging, Burnaby, BC, Canada).
RT-PCR
D5 cells were cultured in CM and different concentrations
of rhTNF-α (3.5, 35, 350 U/ml) or rmIFN-γ (2, 10, 20 ng/
ml) for 2, 4, or 12 hours. To characterize tumor-specific
expression of chemokine, effector T cells (4 × 106) were
cultured alone, with immobilized anti-CD3, with a syn-
geneic, but unrelated sarcoma, MCA-310, or with D5 (4 ×
105) for 6 hours. RNA was extracted from D5 and effector
T cells using the RNeasy mini kit (Qiagen, Hilden, Ger-
many). cDNA was synthesized using 2 ug of total RNA
oligo p(dT)15 (Roche, Mannheim, Germany) and murine
MLV reverse transcriptase (Life Technologies, Karlsruhe,
Germany) according to a standard protocol. Semi-quanti-
tative PCR for different chemokines was performed as
published elsewhere with slight modifications [19]. The
typical amplification reaction contained 1× PCR buffer,
200 mM dNTP, 100 pg of each 3' and 5' primers, and 1 U
of Taq DNA polymerase in 50 μl reaction volume. The
nucleotide sequences of the primers used in the amplifica-
tion reactions are depicted in Table 1. After 1 min of pre-
denaturation at 95°C, thermocycling conditions were 30
sec denaturation at 95°C, 30 sec annealing at 60°C, and
45 sec extension at 72°C. Twenty amplification cycles
were performed for HPRT, 25 cycles for the other gene
amplifications.
Real time reverse transcription-PCR
A two-step reverse transcription-PCR (RT-PCR) protocol
was used for the detection of CCR1, CCR5 and 18S rRNA.
Table 1: Primer sequences of chemokines and control genes
mRNA primer sequence:*
Mip 1α F: ATG AAG GTC TCC ACC ACT GCC CTT G
R: GGC ATT CAG TCC AGG TCA GTG AT
Mip 1β F: GTT CTC AGC ACC AAT GGG CTC TGA
R: CTC TCC TGA AGT GGC TCC TCC TG
KC F: CGG AAT TCG CCA CCA GCC GCC TG
R: CGT CTA GAC TTT CTC CGT TAC TTG G
IP-10 F: CCT ATC CTG CCC ACG TGT TG
R: CGC ACC TCC ACA TAG CTT ACA
RANTES F: CAT CCT CAC TGC AGC CGC CC
R: CCA AGC TGG GTA GGA CTA GAG
MIG F: ATG AAG TCC GCT GTT CTT TTC C
R: TTA TGT AGT CTT CCT TGA ACG AC
MCP-1 F: CTC ACC TGC TGC TAC TCA TTC
R: GCT TGA GGT GGT TGT GGA AAA
TNF-α F: GTT CTA TGG CCC AGA CCC TCA CA
R: TAC CAG GGT TTG AGC TCA GC
GP-100 F: AAA TGC CAA CCA CAG AGG TC
R: CAA GCA TTA TGG TGT CGG TG
HPRT F: GTT GGA TAC AGG CCA GAC TTT GTT G
R: GAG GGT AGG CTG GCC TAT AGG CT
*F = forward = sense = 5'-, R = reverse = antisense = 3'-primer 
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Total cellular RNA was isolated from 1 × 106 DJ2PM cells
according to the manufacturer's instructions (TriReagent,
SIGMA-Aldrich). Genomic DNA contamination was
removed by treatment with RNase-free DNase (Invitro-
gen, Karlsruhe, Germany) for 15 minutes at 37°C. An
aliquot of 1 μg RNA was reverse transcribed with an oligo
(dT) 15 primer using the avian myeloblastosis virus
reverse transcriptase (AMV, first-strand synthesis kit for
RT-PCR, Roche Diagnostics). Complete absence of
genomic DNA was confirmed by control reactions with-
out AMV. Real-time PCR was performed by the LightCy-
cler technology (Roche Diagnostics, Mannheim,
Germany) with SYBR Green fluorescence. PCR amplifica-
tion was performed with the LightCycler Fast Start Reac-
tion Mix SYBR Green I, including a three-segment
amplification protocol: initial denaturation at 95°C for
10 minutes followed by 30 cycles of amplification of 10
seconds at 95°C, 4 seconds at 55°C for CCR1 and CCR5
or 62°C for 18S rRNA, and 5 seconds at 72°C. Primer
sequences are listed in Table 2.
All primers were purchased from Metabion (Martinsried,
Germany). Amplified products were separated on a 2%
TAE agarose gel.
Measurement of cytokines
After activation and expansion effector T cells were
washed, resuspended in CM + IL-2 (60 IU/ml) and seeded
at 4 × 106/well in a 24 well plate (Corning Costar, Cam-
bridge MA.). The cells were either cultured without further
stimulation or stimulated with either 2 × 105 D5, or MCA
310 tumor cells, or immobilized anti-CD3. Supernatants
were harvested after 24 hours and tested for chemokines
by ELISA. Similarly, D5 tumor cells were cultured alone or
with rmIFN-γ or rhTNF-α at the concentrations specified
and supernatants harvested after 24 hours. Release of
MIP-1α, MIP-1β, KC, MCP-1 and RANTES was deter-
mined in duplicate by ELISA using commercially available
reagents (B&D Biosciences, PharMingen, San-Diego, CA).
The concentration of chemokines in the supernatant was
determined by regression analysis.
Detection of CCR expression by flow cytometry
DJ2PM cells (106) were incubated for 24 h in CM media
alone or in CM media containing 20 ng recombinant
murine IFN-γ or 20 ng recombinant murine TNF-α (both
from B&D Biosciences, PharMingen, San-Diego, CA), a
combination of both or supernatants of 24 h anti-CD3
stimulated wt effector T cells. DJ2PM cells were harvested,
washed and stained either with the anti-CCR5-Biotin
mAb or the corresponding IgG2c-Biotin control (B&D
Biosciences, PharMingen) for 20 min at 4°C. Cells were
then washed and stained with streptavidin-PE-Texas-Red
(PE-TR; Caltag, now Invitrogen, CA, USA) for 20 min at
4°C. DJ2PM cells were washed and CCR5 expression was
analyzed using the Dako CyAN flow cytometer (Dako
Colorado Inc., CO, USA).
Chemotaxis assay
Either 105 D5 melanoma cells, 106 effector T cells or both
D5 and effector T cells were plated in CM into the bottom
chamber of a 24- transwell plate (Corning Costar, Cam-
bridge MA.). Control wells contained medium, medium
with 1 ng/ml each of recombinant MIP-1α and MIP-1β
(R&D) or effector T cells cultured in wells precoated with
anti-CD3 (10 μg/ml). DJ2PM cells were incubated with
Carboxyfluorescein Diacetate, Succinimidyl Ester (CFDA-
SE, 0.5 μM in PBS) according to the supplier's instructions
(Invitrogen). In blocking experiments, DJ2PM were incu-
bated at 37°C for 90 min with pertussis toxin (0.05 μg/
ml, 0.5 μg/ml, or 5 μg/ml, Sigma) at 2.5 × 106 cells/ml.
DJ2PM (3.5 × 105 per well) were washed in CM and resus-
pended in 250 ml prewarmed and pH-adjusted CM into
the top chamber of the transwell plates. After 20 hours of
incubation at 37°C, 5% CO2, all cells that had migrated
through the filter to the lower chamber were collected by
a short trypsinization, washed 2 times in FACS buffer
(PBS, 0.5% BSA, 0.02% Na-Azid), blocked with Fc-γ III/II
Receptor (2.4G2, BD Biosciences, San-Diego, CA) and
stained with anti-CD11b antibody (BD Biosciences). The
number of macrophages (i.e., the number of CD11b/
CFDA-SE double-positive stained cells) that migrated into
a well was determined by flow cytometry. Measurement
was performed in the presence of propidium iodide to
exclude dead cells.
Nitric oxide detection
Elicited peritoneal macrophages were generated in
C57BL/6 mice by injecting 5 ml thyoglycolate ip for 3 con-
secutive days. Seven days after the first injection the ani-
mals were killed by CO2, and macrophages were
harvested from the peritoneal cavity by washing with
HBSS, resuspended in CM and allowed to adhere to petri
dishes for 1 hour. Non-adherent cells were removed and
adherent cells were harvested by scraping. The cells were
washed with HBSS and 1 × 105 macrophages plated with
4 × 106 effector T cells. The cells were either cultured with-
Table 2: Primer sequences of chemokine receptors and control 
genes
mRNA primer sequence:*
CCR1 F: CCA CTC CAT GCC AAA AGA CT
R: ACT AGG ACA TTG CCC ACC AC
CCR5 F: CGA AAA CAC ATG GTC AAA CG
R: GTT CTC CTG TGG ATC GGG TA
18SrRNA F: CGG CTA CCA CAT CCA AGG AA
R: GCT GGA ATT ACC GCG GCT
*F = forward = sense = 5'-, R = reverse = antisense = 3'-primer 
sequenceJournal of Translational Medicine 2007, 5:56 http://www.translational-medicine.com/content/5/1/56
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out further stimulation or stimulated by either 2 × 105 D5,
MPR-4 tumor cells, or anti-CD3. Supernatants were har-
vested after 4 hours and the release of NO was determined
in duplicate using GRIES reagent (G4410, Sigma, St.
Louis, MO). The concentration of NO in the supernatant
was determined by regression analysis.
Statistical analysis
The significance of differences in the number of migrating
macrophages and cytokine secretion was determined
using a Student unpaired t-test. Two-sided p values of <
0.05 were considered to be significant.
Results
Adoptive immunotherapy with wt or PKO effector T cells 
promotes rapid infiltration of Mac-1+ and GR-1+ cells
Lungs from mice bearing 4-day established pulmonary
metastases were obtained 24 hours after adoptive transfer
of tumor-specific T cells and frozen sections were stained
with mAbs against CD4, CD8, NK1.1, Mac-1, and GR-1.
Control mice did not receive T cells, but all animals
received treatment with IL-2. Lungs from tumor-bearing
control animals treated with IL-2 alone contained rela-
tively few infiltrating cells (Figure 1, left panel). As
reported by us previously, there were substantial increases
in the number of CD4+, CD8+, Mac-1+, and GR-1+ cells in
the tumor-bearing lungs of mice that received wt (middle
panel) effector T cells (Figure 1) [3]. However, comparing
these results to those obtained after adoptive transfer of
PKO (right panel) effector T cells there were no apparent
differences in the level of infiltrating CD4+, CD8+, Mac-1+,
and GR-1+ cells (Figure 1). NK1-1+ cells were not found in
any lung section, although the Ab did stain a positive con-
trol tissue on the same slide (data not shown).
These results document, that following the adoptive trans-
fer of tumor-specific T cells and IL-2, cells of the innate
immune system, particularly macrophages and granulo-
cytes, infiltrate pulmonary metastases. While it is gener-
ally considered that macrophages serve a "mopping-up"
role following immune-mediated cell death, we won-
dered how PKO effector T cells which lack the capacity for
rapid killing (4 hr cytotoxicity) and require longer periods
of cell-cell contact to induce cell death were apparently
inducing the same rapid influx of Mac-1+ and GR-1+ cells
into the lung [2].
Chemokine expression by effector T cells
The local infiltration of cells from the innate immune sys-
tem following adoptive transfer of wt or PKO effector T
cells suggested the local production of chemokines to
attract cells to the tumor microenvironment. Thus, we
investigated whether the adoptively transfered tumor-spe-
cific T cells might be the source of chemokines responsible
for the infiltration of innate immune cells. Tumor-specific
effector T cells from TVDLN, activated with anti-CD-3 and
expanded in IL-2, were examined for the expression of
mRNA for various chemokines. Chemokine expression in
T cells stimulated with specific tumor (D5) or syngeneic,
but unrelated tumor (MCA-310) was compared to expres-
sion in unstimulated T cells or T cells stimulated with anti-
CD3. Anti-CD3 induced high levels of message for MIP-
1α and MIP-1β. RANTES expression was high in unstimu-
lated effector T cells and did not change following stimu-
lation with anti-CD3 or specific tumor cells. In contrast,
IP-10, MIP-1α and MIP-1β message, which were weakly
expressed in unstimulated effector T cells, showed
increased expression following stimulation with specific
tumor cells or anti-CD3 (Figure 2).
Immunohistochemistry of tumor-bearing lungs of mice 24  hours after immunotherapy with either IL-2 alone (left panel)  or IL-2 and effector T cells from wt mice (middle panel) or  PKO mice (right panel) Figure 1
Immunohistochemistry of tumor-bearing lungs of mice 24 
hours after immunotherapy with either IL-2 alone (left panel) 
or IL-2 and effector T cells from wt mice (middle panel) or 
PKO mice (right panel). Lungs were frozen and sections 
were cut and stained with control IgG, anti-CD4, anti-CD8, 
anti-NK1.1, anti-MAC-1, or anti-GR-1 Abs.Journal of Translational Medicine 2007, 5:56 http://www.translational-medicine.com/content/5/1/56
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Tumor-specific secretion of chemokines
To confirm that cytokines were actually secreted, superna-
tants from effector T cells stimulated with D5, the syn-
geneic, but unrelated sarcoma (MCA-310) or anti-CD3
were assayed for RANTES, MIP-1α and MIP-1β. T cells cul-
tured alone (unstimulated), or stimulated with MCA-310,
did not secrete significant levels of these chemokines (Fig-
ure 3). However, T cells stimulated with their "specific"
tumor (D5), secreted significant (p < 0.05) amounts of all
three chemokines. Since effector T cells generated in
response to vaccination with D5-G6 exhibit a highly
polarized type 1 cytokine profile. These results are consist-
ent with reports correlating RANTES, MIP-1α and MIP-1β
expression with type 1 T cells [20,21]. KC and MCP-1,
which are not secreted by T cells, could not be detected in
the supernatants of unstimulated or anti-CD3 stimulated
effector T cells. However, low levels of both cytokines
were detected in the supernatants of effector T cells stimu-
lated with D5 tumor cells (data not shown), suggesting
that these chemokines were being secreted by the tumor
cells following interaction with tumor-specific type 1
effector T cells.
Chemokine expression and secretion by D5 tumor cells
Although there is evidence that tumor cells constitutively
express and secrete chemokines that can attract macro-
phages [22-24], we did not observe macrophages around
the D5 pulmonary metastases in untreated animals with
established pulmonary metastases or in animals treated
with IL-2. After the chemokines expressed by effector T
cells were identified, we investigated whether chemokines
were also expressed by D5. Interestingly, message for
RANTES was expressed constitutively at low levels
whereas KC, MCP-1, IP-10, MIG, MIP-1α and MIP-1β
were not expressed (Figures 4a, b). However, while mes-
sage for RANTES was detected, D5 cultured in CM did not
secrete substantial amounts of RANTES (data not shown).
Since therapeutic tumor-specific effector T cells secrete the
type-1 cytokines IFN-γ and TNF-α [2,4], we determined
whether chemokine expression by D5 was induced fol-
lowing stimulation with IFN-γ and TNF-α. Twelve hours
of incubation with rmIFN-γ (20 ng/ml) induced mRNA
expression for MCP-1 and MIG and upregulated mRNA
expression for RANTES. Incubation of D5 with rhTNF-α
(3.5 U/ml) induced mRNA expression of KC and MCP-1
MIP-1α MIP-1β RANTES and IP10 mRNA-expression by effector T cells Figure 2
MIP-1α MIP-1β RANTES and IP10 mRNA-expression by effector T cells. Effector T cells were cultured alone (unstimulated 
control), with D5 (specific tumor stimulation), with a syngeneic but unrelated tumor MCA-310 (specificity control), or with 
anti-CD3. T cells were harvested 6 h later to determine MIP-1α MIP-β, RANTES and IP10 mRNA expression. RNA isolated 
from the macrophage cell line J774 was stimulated with IFNγ (20 ng/ml) and LPS (10 μg/ml) for 4 h and used as a positive con-
trol for chemokine message. Negative controls included water instead of cDNA. Hypoxanthine phosphoribosyltransferase 1 
(HPRT) is a commonly used reference gene that was used as a control.
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after only 2 hours. After 12 hours of incubation with
rhTNF-α the expression of MCP-1 and RANTES increased
further and mRNA for IP-10 was detected. While D5
tumor cells cultured without cytokine did not secrete
RANTES, KC or MCP-1, ELISA confirmed that D5 tumor
cells cultured with TNF-α (350 U/ml) secreted all 3 chem-
okines (Figure 5 and data not shown).
Co-culture of T cells and tumor cells stimulate 
macrophage chemotaxis
To confirm the interaction of T cells and tumor cells
released substances that were biologically active and capa-
ble of recruiting monocytes/macrophages we developed a
chemotaxis assay. We assessed the DJ2PM macrophage
cell line for mRNA expression of chemokine receptors for
MIP-1α and MIP-1β, CCR1 and CCR5. The DJ2PM mac-
rophage cell line expresses message for both CCR1 and
CCR5 (Figure 6a). We next examined expression of the
CCR1 and CCR5 by flow cytometry. While the rabbit pol-
yclonal anti-human CCR1 is known to cross-react with
mouse CCR1, background staining using two different
sources of rabbit anti-CCR1 was high and experiments
were not informative (data not shown). However, stain-
ing with the anti-CCR5 mAb detected a significant per-
centage of DJ2PM cells expressing CCR5 following culture
with IFN-γ, IFN-γ + TNF-α, or anti-CD3-stimulated T cell
supernatants (Figure 6b). To show that chemokines
secreted by effector T cells were chemotactic for this mac-
rophage cell line, we performed a chemotaxis assay with
DJ2PM macrophages in the upper well of a transwell
chamber and with D5, effector T cells, or a combination
of both, plated into the lower transwell chamber. The
capacity of the DJ2PM macrophage cell line to migrate in
response to chemokines was confirmed by migration of
macrophage into a lower chamber containing MIP-1α and
MIP-1β (positive control, Figure 7). Unstimulated effector
T cells plated into the lower chamber did not induce the
migration of macrophages into the lower transwell cham-
ber. While D5 tumor cells induced some migration of
macrophages into the lower chamber, this increase did
not reach statistical significance. However, a significant
increase in macrophage migration into lower wells was
observed when effector T cells and D5 tumor cells were
cocultured in the lower chamber (p < 0.05). A significant
increase in DJ2PM cell migration into the lower chamber
was also noticed when effector T cells placed in the lower
chamber were stimulated with anti-CD3 (p < 0.05) (Fig-
ure 7). An increased migration of macrophages was also
observed after stimulation of D5 tumor cells with IFN-γ
(10 ng/ml) or TNF-α (35 U/ml) (data not shown).
For further investigation of the nature of the chemotactic
activity produced following anti-CD3 stimulation of
tumor-specific T cells or coculture of D5 with D5-specific
effector T cells, we treated DJ2PM macrophages with PTx
(0.5 mg/ml). Chemokines bind to seven-transmembrane-
domain receptors that are coupled to heterotrimeric Gi
proteins. It is well established that chemokine-induced
Secretion of RANTES (a), MIP-1α (b) and MIP-1β (c) by effector T cells Figure 3
Secretion of RANTES (a), MIP-1α (b) and MIP-1β (c) by effector T cells. Effector T cells generated from D5-G6 TVDLN wt 
mice were assessed for tumor-specific chemokine release. T cells (4 × 106/ml) were cultured alone, with anti-CD3, MCA-310 
(2 × 10 5/ml), or with D5 (2 × 105/ml). Supernatants were harvested 18–24 h later for quantification of RANTES, Mip-1α and 
Mip-1β. Cytokine release into the supernatant was determined by ELISA using a standard kit. Data are presented as the mean 
± SE of three independent experiments. The limit of detection for RANTES, MIP-1α and MIP-1β was 10 pg/ml. * p < 0.05
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migration is completely inhibited by treatment of the cells
with PTx, which inhibits Gai and Ga0 proteins [25]. In
these studies, incubation of DJ2PM with either 0.05 μg/
ml, 0.5 μg/ml or 5 μg/ml of PTx completely inhibited the
migration towards anti-CD3 stimulated T cells and T cells
stimulated with D5, suggesting that heterotrimeric G-pro-
teins are involved in the signal transduction pathway of
the T cell-induced DJ2PM migration (Figure 7 and data
not shown). Together, these data document that D5-spe-
cific effector T cells with therapeutic function in adoptive
a) mRNA-expression of KC, MCP-1, IP-10, RANTES and MIG in unstimulated and stimulated D5 tumor cells Figure 4
a) mRNA-expression of KC, MCP-1, IP-10, RANTES and MIG in unstimulated and stimulated D5 tumor cells. D5 tumor cells 
were cultured alone or stimulated with IFN-γ (2, 10, 20 ng/ml) or TNF-α (3.5, 35, 350 U/ml) for 2 and 12 hours. Tumor cells 
were harvested and mRNA expression determined by RT-PCR. b) Chemokine mRNA-expression of MIP-1α and MIP-1β in 
unstimulated and stimulated D5 tumor cells. D5 tumor cells were cultured alone or stimulated with IFN-γ (20 ng/ml) and TNF-
α (350 U/ml) for 2 and 12 hours. D5 tumor cells were harvested and mRNA expression determined by RT-PCR. RNA isolated 
from the macrophage cell line J774 was stimulated with IFNγ (20 ng/ml) and LPS (10 μg/ml) for 4 h and used as a positive con-
trol. Negative controls included water instead of cDNA.
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transfer studies are capable of inducing chemotaxis of a
macrophage cell line if stimulated with specific tumor or
anti-CD3. They also demonstrate that D5 melanoma cells
exposed to TNF-α or IFN-γ can lead to the release of chem-
okines that are biologically active and capable of inducing
chemotaxis of a macrophage cell line.
Activation of macrophages by effector T cells
To investigate whether macrophages can be activated by
effector T cells, thioglycolate-elicited peritoneal macro-
phages from wt C57BL/6 mice were cultured with effector
T cells generated from wt and PKO mice. Unstimulated
effector T cells from wt and PKO mice did not induce the
secretion of NO from macrophages. Furthermore, secre-
tion of NO was not observed when peritoneal macro-
phages were co-cultured with D5 or the syngeneic tumor
MPR-4, or after stimulation of effector T cells with MPR-4.
However, significant NO secretion was observed when
macrophages were incubated with wt or PKO effector T
cells activated with anti-CD3 or D5 (Figure 8).
Discussion
A number of groups, including ours, have reported that T
cells from mice deficient in specific effector molecules can
still mediate tumor regression in adoptive transfer experi-
ments [2-4]. Although tumor regression in these models is
clearly T cell-mediated, the specific mechanism(s) by
which tumors are destroyed have not been fully character-
ized. Further, the potential contributions of components
of the innate immune system to tumor regression follow-
ing adoptive T cell immunotherapy have not been stud-
ied. Usually, one thinks about the initial activation of the
innate immunity, which leads to the activation of an
adaptive immune response. The converse may also be
true.
Hung et al. demonstrated that CD4+ T cell-dependent
immunity elicited by vaccination with a GM-CSF gene-
modified B16 tumor was dependent on both macro-
phages and granulocytes [26]. Based on this report and
our own demonstration of substantial infiltrates of mac-
rophages and granulocytes in pulmonary metastases
twenty-four hours following adoptive transfer of tumor-
specific T cells, we initiated studies to explain these obser-
vations.
Macrophages play a role in both, innate and adaptive
immune responses. They process and present antigens
and act by orienting adaptive responses toward a type I or
type II phenotype, as well as by expressing specialized and
polarized effector functions [27-30]. Mantovani et al.
showed that macrophages, like T cells, can be segregated
into subsets that differ in their receptor expression pat-
tern, cytokine and chemokine production, and effector
functions [21]. Cytokines and microbial products deter-
mine the polarization of mononuclear phagocytes. IFN-γ
alone or in concert with microbial products (LPS) or other
cytokines (e.g. TNF-α), polarizes macrophages towards a
type-1 (M1) phenotype. M1 macrophages typically have a
high capacity to present antigen, secrete large amounts of
interleukin-12 (IL-12) and IL-23, and produce NO and
reactive oxygen intermediates [31]. M1 macrophages were
shown to be tumoricidal [21,32-36]. In contrast, M2
polarized macrophages are characterized by an IL-10high
and IL-12low phenotype. They are induced by immune
complexes (IC), LPS and the type-2 cytokines IL-4 and IL-
13 [29,37]. Macrophages, spontaneously infiltrating
tumor, were shown to be M2 polarized macrophages pro-
moting tumor progression [28,38].
Macrophages are attracted towards sites of infection and
tumor deposits by chemokines. Chemokines can also
polarize macrophages and influence the tumor environ-
D5 tumor cells were cultured with TNF-α (350 U/ml) or  IFN-γ (20 ng/ml) for 24 hours and culture supernatants  tested for secretion of KC and MCP-1 by ELISA (mean of 2  experiments) Figure 5
D5 tumor cells were cultured with TNF-α (350 U/ml) or 
IFN-γ (20 ng/ml) for 24 hours and culture supernatants 
tested for secretion of KC and MCP-1 by ELISA (mean of 2 
experiments).
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ment in ways that can promote or retard tumor growth
[21]. Therefore, we investigated whether tumor-specific T
cells with therapeutic activity could attract macrophages
by the coordinated, tumor-specific release of chemokines.
Unstimulated effector T cells did not secrete chemokines.
In contrast, anti-CD3 and tumor-specific stimulation of
effector T cells resulted in secretion of MIP-1α, MIP-1β
and RANTES which have been positively correlated with a
type-1 immune response [9-11]. RANTES, MIP-1α, and
MIP-1β are strongly chemotactic for mononuclear cells
a) CCR1 and CCR5 mRNA-expression in unstimulated and stimulated DJ2PM macrophages Figure 6
a) CCR1 and CCR5 mRNA-expression in unstimulated and stimulated DJ2PM macrophages. DJ2PM macrophages were cul-
tured alone or stimulated with IFN-γ (20 ng/ml) or TNF-α (35 U/ml) and mRNA expression determined by RT-PCR. b) Mean 
percentage of DJ2PM cells expressing CCR5 receptor as determined by flow cytometric analyses. Cells were stained with spe-
cific mAb or isotype control. Graph shows the percentage of PE-TR positive DJ2PM cells (mean ± SEM). Histograms with * 
exhibit significantly (*p = 0.01) greater expression of CCR5 compared to isotype controls. Data are a summary of 3 consecu-
tive experiments.
a)  
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
8
S
r
R
N
A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
C
R
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
C
R
5
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
8
S
r
R
N
A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
C
R
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
C
R
5
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
8
S
r
R
N
A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
C
R
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
C
R
5
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
8
S
r
R
N
A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
C
R
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
C
R
5
 
 
Stimulation 
       None            TNF-α            IFN-γ             None  
          (no AMV) Journal of Translational Medicine 2007, 5:56 http://www.translational-medicine.com/content/5/1/56
Page 11 of 14
(page number not for citation purposes)
and DC [39]. Further, we note that message for these
chemokines was detectable in T cells as early as 6 hours
following stimulation with anti-CD3, suggesting that
monocyte infiltration to tumor sites could be triggered
rapidly following adoptive T cell transfer. We confirmed
that some component of the secreted molecules was bio-
logically active as tumor-specific stimulation of effector T
cells or D5 exposed to IFN-γ or TNF-α induced the chem-
otaxis of the DJ2PM macrophage cell line in vitro. Further,
preincubation of DJ2PM with PTx completely inhibited
macrophage migration towards effector T cells, suggesting
that heterotrimeric G-proteins are involved in the signal
transduction pathway responsible for the chemokine-
induced macrophage migration [25].
Furthermore it was shown earlier, that MIP-1α, MIP-1β
and RANTES influence the polarization of T cells towards
a type- phenotype [11]. In the D5 model we appreciate
that the endogenous immune response that occurs fol-
lowing adoptive transfer is critical for the cure and devel-
opment of long-lived immunity in treated animals [40].
The influx of macrophages with an M1 profile may facili-
tate long-lived immunity by promoting the priming and
expansion of endogenous tumor-specific type1 T cells.
Besides the chemotactic effect on macrophages and its
potential to influence the polarization of T cell responses
there is evidence that MIP-1α can directly affect the meta-
static potential of melanoma cells. Van Deventer et al.
showed that MIP-1α-transfected B16 F10 melanoma cells
formed significantly fewer pulmonary metastases as com-
pared to tumor cells that did not express MIP-1α [41].
Whether RANTES, MIP-1α and MIP-1β are direct growth
inhibitors of D5 tumors remains to be determined.
In contrast to type-1 cytokines secreted by effector T cells,
which have been positively correlated with tumor rejec-
tion, the role of chemokines constitutively secreted by
tumors is somewhat controversial [20,42-44]. D5
expressed low levels of RANTES and KC constitutively,
however, very few macrophages were identified in
untreated D5 pulmonary metastases. In contrast to our
observation, Nesbit et al. and Haghnegahdar et al. showed
that melanoma cells secrete low levels of MCP-1 inducing
the accumulation of tumor-associated macrophages and
promoting tumor progression [23,45]. Furthermore
NO release of thioglycolate-elicited macrophages Figure 8
NO release of thioglycolate-elicited macrophages. Thioglyco-
late-elicited peritoneal macrophages and effector T cells (TE) 
were plated into a 24-well plate and co-cultured without or 
with D5, MPR-4 (a syngeneic but unrelated tumor), or anti-
CD3. Macrophages and tumor cell co-cultures without the 
addition of effector T cells was an additional control. Super-
natants were harvested after 4 hours and the release of NO 
determined in duplicate by GRIES reagent using commercially 
available reagents. Data are presented as the mean of three 
independent experiments (SEM) * p < 0.05
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Chemotaxis-assay of DJ2PM macrophages either pretreated  with (black columns) or without (white bars) PTx (0.5 g/ml) Figure 7
Chemotaxis-assay of DJ2PM macrophages either pretreated 
with (black columns) or without (white bars) PTx (0.5 g/ml). 
Migration towards serum control, MIP-1α/MIP-1β, effectotr 
T cells (TE), D5 or D5 co-incubated with TE was determined 
after 4 hours. MIP-1α/MIP-1β, TE, D5 and TE co-cultured 
with D5 were plated into the bottom chamber of a 24 well 
transwell plate for 12 hours. Subsequently 3.5 × 105 perito-
neal macrophages (DJ2PM) were added to the top chamber 
for 4 hours. The number of macrophages that migrated into 
the lower chamber was determined by flow cytometry as the 
percentage of CD11b+/CDFA-SE+ cells. Data are presented 
as the mean ± SE of three independent experiments (* p < 
0.05).
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melanoma cells were shown to express IL-8, Gro-α, Gro-β
and MCP-1, all of which are implicated in tumor growth
and progression [45].
Our own data shows that chemokine secretion by D5 was
markedly upregulated after stimulation with the type-1
cytokines, IFN-γ and TNF-α, expressed by therapeutic
tumor-specific effector T cells. This observation is consist-
ent with findings by Sonouchi et al. who found a signifi-
cant increase of KC, MCP-1 and IP-10 mRNA expression
in RENCA kidney cancer cells after stimulation with IFN-
γ, IFN-α and IL-2 [46]. Together, these findings support a
model where tumor-specific T cells recognize tumor cells
in situ and provide an initial trigger, delivering chemok-
ines and cytokines at the tumor site. In addition to chem-
okines directly recruiting granulocytes and monocytes,
the type 1 cytokines also induce tumor metastases to
secrete additional chemokines, amplifying the recruit-
ment of innate effector cells. In this model it is the combi-
nation of events that lead to the infiltration of monocytes
and granulocytes resulting in T cell-mediated tumor
destruction. In other models the same cytokine cascade
may lead to the production of immune suppressing fac-
tors (IL-10, TGF-β, and VEGF), resulting in immune sup-
pression and tumor progression. This explanation may
shed light on the apparent controversy regarding the role
of inflammation in tumor progression/regression.
Monocyte chemoattractant protein-1 (MCP-1, CCL2) is
expressed in inflammatory conditions, is a chemoattract-
ant for monocytes and T lymphocytes, and plays a pivotal
role in autoimmune diseases [47]. We were able to show
that MCP-1 expression by D5 is strongly induced follow-
ing culture with effector T cells or the inflammatory
cytokines IFN-γ and TNF-α. Therefore, one explanation
for the influx of macrophages is that effector T cells, fol-
lowing recognition of specific tumor, induce the expres-
sion and secretion of high levels of MCP-1 by D5 tumor
cells which in turn results in the influx of macrophages,
eventually aiding and/or leading to tumor destruction. In
contrast to this explanation, Peng et al. showed that neu-
tralizing MCP-1, secreted by the MCA-205 sarcoma,
improved the therapeutic efficacy of tumor-specific effec-
tor T cells in mediating regression of established pulmo-
nary metastases [48]. Future studies will be required to
delineate the role of MCP-1 in the D5 melanoma model.
Besides MCP-1, IP-10, and MIG expression by D5 were
also upregulated following exposure to TNF-α and IFN-γ,
respectively. Arenberg et al. were able to show that intra-
tumoral injection of IP-10, or MIG led to reduced tumor
growth in a SCID mouse model of NSCLC and postulated
an anti-angiogenic effect of these 6C-kines [44]. This was
confirmed by Palmer et al. who demonstrated that M1
polarized macrophages secrete the CXC chemokines IP-10
and MIG which were shown to have anti-angiogenic prop-
erties and to inhibit tumor progression [49]. Interestingly
no effect of 6C-kines on the growth of a human lung can-
cer cell line (A549) or on the infiltration of leukocytes
into established tumors of SCID-mice was observed [44].
Tannenbaum et al. showed that antibodies against IP-10
and MIG blocked IL-12 inducible tumor regression and
decreased the amount of tumor-infiltrating T cells in the
murine kidney cancer tumor model RENCA [50]. Thus it
can be speculated that tumor regression induced by IP-10
and MIG is mediated by the release of IL-12 that in turn
promotes the induction of tumor-specific T cells with a
type 1 cytokine profile. This positive feedback loop may
help to explain why the Renca tumor cell line is so
strongly immunogenic. It has to be evaluated further
whether this is also true in our melanoma tumor model.
Future studies will need to provide a more quantitative
and qualitative analysis of inflammatory cell infiltrates.
Current efforts are directed at using multiparameter flow-
based methods to characterize monocytes and macro-
phages. Such characterization of the innate immune cells
infiltrating the tumor site may provide additional insights
into the effector mechanisms that are operational during
T cell-mediated tumor destruction.
Conclusion
We show that tumor-specific T cells with therapeutic effi-
cacy secrete chemokines in response to tumor-specific
stimulation. While this seems obvious, studies dissecting
the mechanism of T cell-mediated tumor regression have
focused on perforin, IFN-γ, TNF and Fas-L. We are una-
ware of a report that considers the influx of innate cells as
a possible effector mechanism in T cell-mediated regres-
sion of pulmonary metastases following adoptive immu-
notherapy. Instead, this influx of macrophages is
commonly considered a response to "mop-up" dead cells.
Here we show that the chemokines secreted by T cell –
tumor co-cultures are chemotactic for macrophages in
vitro and may explain the rapid accumulation of macro-
phages at the site of pulmonary metastases following
adoptive immunotherapy with therapeutic T cells. Fur-
thermore, tumor-specific effector T cells were able to
change the chemokine expression pattern of D5 tumor
cells such that they secreted chemokines that were chem-
otactic for macrophages in vitro. This provides an "ampli-
fication" pathway to augment the chemokines secreted by
T cells. Finally, we show that co-cultures of effector T cells
and tumors can promote activation of macrophages that
secrete NO. The tumoricidal activity of NO secreted by
macrophages may account for some of the therapeutic
efficacy following adoptive T cell immunotherapy. These
observation provide additional insights into the multi-
tude of mechanisms potentially involved in T cell-medi-
ated tumor regression as well as a possible explanation forJournal of Translational Medicine 2007, 5:56 http://www.translational-medicine.com/content/5/1/56
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the heterogeneity in clinical responses observed among
patients on clinical adoptive immunotherapy trials.
Future studies will need to characterize whether failure to
express chemokines following exposure to IFN-γ and/or
TNF-α represents a new class of resistance mechanisms
employed by tumors to escape immune destruction.
Finally, these observations may also prove useful in
explaining why inflammation can be associated with
tumor progression in some models and tumor regression
in others.
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